In 2002, Buchang Pharmaceutical was awarded the title of "Honest Tax Paying Enterprise" by People's Republic of China (PRC) State Taxation Administration of The People's Republic of China and the All-China Federation of Industry and Commerce. In 2006, the company was named "Top Ten Most Growing Enterprises in China Pharmaceutical Industry". In 2007, the company was awarded the title of "People's Assured Pharmaceutical Enterprise", and in August of the same year, it was awarded the "Overall Evaluation List of Pharmaceutical Brands in China"-the highest award of the year among the top ten brands of pharmaceutical enterprises in China. In 2008, the company won the honorary titles of "Top 2007 China Commercial Science and Technology 100" and "Top 500 Private Science and Technology Enterprises in China in 2008". In March 2008, the founders of the company, Professor Zhao Buchang and Dr. Zhao Chao, were both elected as deputies to the 11th National People's Congress, which was the highest honor and the greatest encouragement given by the party and the state. In 2009, Professor Zhao Buchang was awarded "60 people in 60 years of pharmaceutical industry in China", and Mr. Zhao Tao was awarded "Labor Medal for Enriching People and Prospering Shandong". Dr Zhao Chao was awarded "Excellent Entrepreneurial Entrepreneur in Shaanxi Province" and "Top Ten Economic Figures in Shaanxi in 2009". The company has always regarded scientific and technological innovation as the main driving force for enterprises to become bigger and stronger. In 20 10, it paid 960 million yuan in taxes, and nearly 4 billion yuan for the country. In 2009, it entered the top ten of "Top 100 Pharmaceutical Industries in China" and ranked ninth. 20 10 1 1, Danhong injection won the "Gold Award of the First Traditional Chinese Medicine Patent in China"; "Buchang Naoxintong" won the "Top Ten Brands of Traditional Chinese Medicine"; Dr. Zhao Chao was awarded the honorary title of "Economic Man in the Decade of Western Development".
The company has the courage to undertake social responsibilities and has established a good corporate image in the public mind. Since 1997, the company has been among the top taxpayers of local private enterprises for many years. Donations to social welfare undertakings exceeded 300 million yuan. In the 2008 Wenchuan earthquake, the company donated 5 million yuan and won the "Hope Project Outstanding Contribution Award for Earthquake Relief" from Shaanxi Provincial Committee of the Communist Youth League. In June 2009, initiated by the company, China Society of Traditional Chinese Medicine, Beijing Red Cross Society and some well-known hospitals in the capital jointly launched "* * * Casting China Heart-Cardiovascular and Cerebrovascular Health Care Plan in the Western Region" to provide free assistance to patients with cardiovascular and cerebrovascular diseases in poor western regions. 20 10 In February, the company donated 1 100 million yuan again to promote the sustainable development of the project "* * * Casting China Heart". In April, the company donated 5 million yuan to Yushu disaster area. "20 10 China Charity Ranking" was selected, ranking second among the "Top Ten Charity Enterprises" by step size; On the "20 10 Hurun Charity List", Professor Zhao Buchang and Zhao Tao are known as "China Charity Philanthropists". The company won the "China Social Responsibility Award for Medical and Health Industry" for two consecutive years.
Buchang Pharmaceutical will take "modernization of Chinese medicine and internationalization of the market" as its own responsibility, strive to build the first brand of Chinese medicine in China, and constantly contribute to the health of Chinese people!
In the development of more than ten years, enterprises have always put the political concept of "listening to the Party, taking the socialist road, respecting the leaders of governments at all levels and operating according to law" in the first place, adhering to the image concept of "professional quality and health messenger", taking "a century-old enterprise" as the development goal, and insisting on "taking the market as the center, being anxious about the market and thinking about the market" in the course of operation, which has been formed. Its unique and advanced corporate culture has become an important force for the rapid development of enterprises.
Since 1997, Buchang Group has been rated as the largest taxpayer of private enterprises in Shaanxi Province for many years, paying taxes for the country 1 1 billion. From June 5th to February, 2002, Buchang Group was awarded as "Honest Tax Paying Enterprise" by State Taxation Administration of The People's Republic of China, People's Republic of China (PRC) and All-China Federation of Industry and Commerce. In 2006, Buchang Group won the title of "Top Ten Most Growing Enterprises in China Pharmaceutical Industry". In June 2007, Buchang Group won the honor of "People's Relieved Medicine Enterprise" and Buchang Danhong Injection won the honor of "People's Relieved Medicine". In August, 2007, Buchang Group won the "Golden Spectrum Award", the highest annual award in the overall evaluation list of pharmaceutical brands in China-the top ten brands of pharmaceutical enterprises in China. In 2008, Buchang Group ranked 17 in the list of the top 100 pharmaceutical industries in China. In March 2008, Professor Zhao Buchang, Chairman of Buchang Group, was elected as the representative of the 11th National People's Congress, and Zhao Chao, Chairman of Buchang Pharmaceutical, was elected as the representative of the 11th National People's Congress.
Buchang Group has always attached great importance to scientific research and product development. The Group spends 65,438+00% of its sales revenue on scientific research and product development every year, adheres to the road of independent research and development, and owns more than 50 exclusive intellectual property products. The chairman and president have worked out the product development strategy of high, medium, low, long, medium and short for the company. Naoxintong series products and other high-tech products are continuously introduced, such as Buchang Wenxin Granule, Buchang Beitong Danhong Injection, Buchang Delisheng Injection, etc. The business scope covers cardiovascular and cerebrovascular diseases drugs, anti-tumor pure Chinese medicine injections, gynecological drugs, digestive products, generic drugs, western medicines, OTC products, community health education and medical devices. Ten GAP planting bases, strong product reserves, market network and advanced corporate culture constitute the core competitiveness of Buchang. In 2008, Buchang Group won the title of "Top 2007 China Commercial Technology Enterprises 100". In June of the same year, Buchang Group won the honorary title of "Top 500 Private Sci-tech Enterprises in China in 2008". Its representative product "Buchang Naoxintong" won the Eureka Gold Award in the 42nd World Invention Expo; The title of "Consumer Trusted Product" issued by China Consumer Protection Foundation; In 2004, it was rated as "the first choice brand with satisfactory product quality for consumers in China cardiovascular and cerebrovascular drugs market".
Paying attention to the research and development of high-tech new drugs is the general idea of scientific research and development in recent years. For example, biopharmaceuticals, purification technology of traditional Chinese medicine monomer, Parker process technology of drugs, and research and development of cephalosporin antibiotic intermediates are all involved in the pharmaceutical industry of the group. The success of these aspects will accelerate the internationalization of step size and stabilize the foundation of the century-old step size industry.
Buchang Group insists on "honesty-based, steady operation", pays attention to product quality, and puts forward that "curative effect is the last word". Planting and production in strict accordance with national GAP and GMP standards and strict quality control have won wide acclaim for enterprises.